Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BD Diagnostics, a segment of Becton, Dickinson and Company, and a global medical technology company, has received the FDA pre-market approval for the BD FocalPoint GS imaging system.
Subscribe to our email newsletter
According to the company, this innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
Vincent Forlenza, executive vice president of BD, said: “The launch of the BD FocalPoint GS System represents a key milestone in our effort to expand BD’s presence in cancer diagnostics.
“It is the first in a series of innovative products aimed at improving the detection and clinical management of cancer, resulting from our TriPath acquisition.”